Skip to main content

TimeLogic Expands Product Line and Staff In Response to Bullish Accelerator Market


Despite an economic climate that has forced many organizations to limit their capital spending, Time Logic CEO Jim Lindelien said that the market for his company’s bioinformatics accelerators not only remains strong, but continues to expand.

“Accelerated bioinformatics is a growing market for us because of our R&D commitment, and a market we will remain committed to for the long haul,” said Lindelien, who said the company invested over 25 percent of last year’s gross revenues into new product development activities. According to Lindelien, this level of R&D commitment “significantly outpaces industry norms in computing.” IBM, for example, spent six percent of its gross 2000 revenue on R&D.

In addition, Lindelien said, despite the large R&D investment, TimeLogic closed last year with a profit, “as we have done for 19 of the past 20 years.”

The company plans to continue this level of R&D investment in 2001.

TimeLogic’s development efforts have paid off in the form of its latest product, the My DeCypher accelerated workstation to be released as part of a recently formed partnership with Compaq. The workstation, which will be sold through Infocom, TimeLogic’s distribution partner in Japan, is based on Compaq’s Deskpro Proliant platforms and is the company’s first product roll-out on a Compaq system.

Lindelien described the My DeCypher as an “introductory” accelerator platform that comes in at a far lower price point “for small business and academic groups who do not have the budget or technical resources to build and administer large clusters of machines.”

While a typical DeCypher installation can range between $150,000 and $300,000 and replace the equivalent of 300-1000 CPUs, the My DeCypher should run around $40,000 to $50,000 and replace a server farm of 50-100 CPUs, Lindelien said.

In addition to the Compaq partnership, TimeLogic also formed a non-exclusive technical and marketing alliance with Sun Microsystems last year. “Our revenue opportunities with Sun are limited only by TimeLogic’s ability to grow at a head-spinning pace,” said Lindelien.

And TimeLogic’s product line isn’t the only part of the company that’s expanding. The company recently doubled its floor space by moving its corporate offices from Incline Village, Nev., to Crystal Bay, Nev., and is currently hiring additional technical and management staff.

Lindelien reported that the company recently made its first sales into Thailand, Denmark, and New Zealand and expects to exceed its sales figures from last year.

— BT

Filed under

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.